Raab S S
Department of Pathology, Allegheny University of Health Sciences, Allegheny General Hospital, Pittsburgh, PA, USA.
Clin Lab Manage Rev. 1998 Mar-Apr;12(2):91-6.
Although most laboratories practice 10% manual rescreening of negative Pap tests, the cost-effectiveness of this and other rescreening strategies rarely has been evaluated. A decision model was created in which rescreening strategies were compared with nonrescreening strategies in terms of the number of false negative and positive diagnoses, cancers, life expectancy, and cost-effectiveness. The 10% rescreening with a repeat Pap test strategy yielded almost no gain in life expectancy in comparison to an equivalent strategy with no rescreening. A 100% rescreening strategy generally was more cost-effective than a no-rescreening strategy at costs of rescreening varying from $2 to $10 per patient. We conclude that if the rescreening cost is low, 100% rescreening strategies are more cost-effective than nonrescreening strategies.
尽管大多数实验室对阴性巴氏试验进行10%的人工复查，但这种及其他复查策略的成本效益很少得到评估。创建了一个决策模型，在该模型中，就假阴性和阳性诊断数量、癌症、预期寿命和成本效益而言，将复查策略与不复查策略进行了比较。与不进行复查的等效策略相比，采用重复巴氏试验策略进行10%的复查在预期寿命方面几乎没有增加。在每位患者2至10美元的复查成本下，100%的复查策略通常比不复查策略更具成本效益。我们得出结论，如果复查成本较低，100%的复查策略比不复查策略更具成本效益。
